BBC
Virtus LifeSci Biotech Clinical Trials ETF
Price Chart
Latest Quote
$44.83
+1.81 (+4.21%)
Current Price
| Previous Close | $43.02 |
| Open | $43.36 |
| Day High | $45.52 |
| Day Low | $44.03 |
| Volume | 26,884 |
Fund Information
| Quarterly Dividend / Yield | N/A / 1.47% |
| Net Assets | $44.63M |
| Expense Ratio | 0.65% |
| Category | Health |
| Fund Family | Virtus |
| Net Asset Value | $43.08 |
| Premium/Discount | 4.06% |
| Quarterly Dividend Yield | 1.47% |
| Exchange | PCX |
📊 ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $42.72 |
| SMA50 | $43.94 |
| SMA200 | $37.61 |
| RSI | 53.99 |
| ATR | 1.5017 |
| Rel Volume | 1.39 |
Performance History
| Week | +10.23% |
| Month | +8.90% |
| Quarter | +12.38% |
| 6 Months | +14.54% |
| YTD | +19.13% |
| Year | +129.57% |
| 3 Years | +80.15% |
| 5 Years | -8.93% |
| 10 Years | +149.80% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $44.83 | 26,884 |
| 2026-06-16 | $43.02 | 3,200 |
| 2026-06-15 | $43.63 | 5,300 |
| 2026-06-12 | $43.03 | 6,600 |
| 2026-06-11 | $42.22 | 6,000 |
| 2026-06-10 | $40.67 | 9,400 |
| 2026-06-09 | $41.41 | 53,000 |
| 2026-06-08 | $40.90 | 10,000 |
| 2026-06-05 | $40.66 | 20,300 |
| 2026-06-04 | $42.96 | 13,300 |
| 2026-06-03 | $41.89 | 9,000 |
| 2026-06-02 | $41.71 | 21,100 |
| 2026-06-01 | $43.86 | 14,800 |
| 2026-05-29 | $44.57 | 9,700 |
| 2026-05-28 | $43.70 | 3,000 |
| 2026-05-27 | $43.56 | 6,100 |
| 2026-05-26 | $43.37 | 6,200 |
| 2026-05-22 | $42.71 | 68,100 |
| 2026-05-21 | $43.33 | 43,700 |
| 2026-05-20 | $42.47 | 51,800 |
| 2026-05-19 | $40.54 | 39,700 |
| 2026-05-18 | $41.17 | 97,700 |
About Virtus LifeSci Biotech Clinical Trials ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
📰 Latest News
Biotech ETF (BBC) Touches Fresh 52-Week High
Zacks • 2026-04-10T14:02:00Z
Can ETF Winners of Q4 of 2025 Rally in Q1 of 2026?
Zacks • 2026-01-06T16:00:00ZBiotech ETF (BBC) Hits New 52-Week High
Zacks • 2025-12-01T11:00:00Z
The Zacks Analyst Blog Highlights LLY, EPHE, BBC, HELX, XHS and SURI
Zacks • 2025-11-25T08:44:00Z
Best-Performing ETFs of Last Week: Healthcare Rules
Zacks • 2025-11-24T15:00:00Z
Best-Performing ETFs of Last Week
Zacks • 2025-11-17T12:43:00Z
Biotech ETFs Hovering Around a 52-Week: Here's Why
Zacks • 2025-10-30T13:00:00Z
Trade War or Not, Specific Industry ETFs Are in Sweet Spots
Zacks • 2025-10-16T10:51:00Z
The Zacks Analyst Blog Highlights BWET, GOEX, SLVP, LIT and BBC
Zacks • 2025-09-10T13:49:00Z
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.